New ALK inhibitor ensartinib tested in first human trial for lung cancer
NCT ID NCT01625234
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors. The trial had two parts: a dose-finding phase and an expansion phase focused on ALK-positive lung cancer patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ensartinib (X-396), an oral ALK inhibitor drug
What this could lead to
If it works, this could provide a new treatment option for people with ALK-positive non-small cell lung cancer that has stopped responding to other therapies.
What could go wrong
This is an early first-in-human study, so the drug may not prove effective or may cause unexpected side effects. Results are preliminary and need confirmation in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope National Med Ctr
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
New York University Langone Medical Center
New York, New York, 10016, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
Stanford University
Stanford, California, 94305, United States
-
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203, United States
-
UCSD Moores Cancer Center
La Jolla, California, 92093, United States
-
University of Southern California Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Wisconsin Carbone Cancer Ctr
Madison, Wisconsin, 53792, United States
-
Vanderbilt University
Nashville, Tennessee, 37240, United States
-
Walter Reed National Military Medical Center
Bethesda, Maryland, 20889, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States